An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients ...

Takeda and Protagonist Therapeutics' hepcidin mimetic rusfertide has been approved by the FDA to treat polycythaemia vera (PV ...

Since 2001, International Overdose Day has been observed as a moment to remember those lost to overdose and renew society’s ...

The new acquisition is Lilly's ninth since the start of the year, coming just a few weeks after it agreed to buy psychedelic ...

South Korea’s mRNA ecosystem is rapidly advancing, fueled by progress from companies like GC Biopharma and EyeGene in ...

Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, trumpeting new data for its ...

Through increased government investment in AI and in silico technologies, and prominent partnerships and milestones from companies like 1st Biotherapeutics, Galux, Hanmi Pharm, and LG Research AI, ...

Cytokinetics has revealed the highly anticipated data from the ACACIA-HCM study of Myqorzo, which promises to take the cardiac myosin inhibitor into new territory for the class. First teased in May, ...

A new, universal definition for a heart attack or myocardial infarction (MI) recognises that there are many different ...

Since taking effect in August 2024, the EU AI Act (Regulation (EU) 2024/1689) has categorised AI tools by risk level. For ...

Sword Health, a digital therapeutics company that started in the physical therapy space, has acquired digital mental health ...

The FDA issued approvals for Pfizer and Moderna's 2026 COVID-19 vaccines on Thursday, but is recommending them for the same ...